Hosted on MSN1mon
Tenaya Therapeutics announces option repricing to retain staffAmid these developments, Tenaya announced the departure of Leone Patterson, its Chief Financial and Business Officer, and is currently seeking a replacement. Despite this, analyst firms such as H ...
the granddaughter of Chief Tenaya and the last survivor of the expulsion of the Ahwahneechees in 1851. In 1930, he persuaded his superiors to let him and two colleagues conduct a four-year survey ...
Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy MyPEAK-1 Cohort 1 Data ...
As of December 31 cash, cash equivalents and investments in marketable securities were $61.4M compared to $104.6M as of December 31. With the ...
Tenaya’s Chief Executive Officer, will participate in TD Cowen’s 45 th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference 2025. Details are as follows ...
We look forward to sharing data from both the TN-201 MyPEAK-1 clinical trial for -associated ARVC in the months ahead,” said Faraz Ali, Chief Executive Officer of Tenaya. “The recent financing ...
Chief Executive Officer of Tenaya. “The recent financing with support from existing and new shareholders allows us to maintain our focus on driving our gene therapy programs for cardiomyopathies ...
The live and archived webcast of the presentation and fireside chat may be accessed from the Investors section of Tenaya’s website. A replay of the webcasts will be available on the Tenaya website for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results